Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

Launched by EMORY UNIVERSITY · Oct 1, 2021

Keywords

ClinConnect Summary

The CHAMPS Study is focusing on improving the rate of HPV vaccination among adults living with HIV, who are at a much higher risk for HPV-related diseases, including anal cancer. This study will use a proven program called the CDC's 4 Pillars Transformation Program, which has helped increase HPV vaccinations in the general population. The goal is to tailor this program specifically for people living with HIV in rural Georgia. Researchers will work with three HIV clinics and aim to enroll 365 participants aged 18 to 45 who are HIV positive and have not received the full three-dose HPV vaccine series.

To be eligible for this study, participants must be between 18 and 45 years old, able to read and speak English, and not have received the HPV vaccine before. They should also be in good health and not have any serious allergies that would prevent them from getting the vaccine. Throughout the study, participants can expect to receive training and resources related to the HPV vaccine, helping them understand its importance in preventing serious health issues. This study is an important step in making sure that individuals living with HIV have access to effective preventive care against HPV.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • HIV positive
• • 18-45 years of age
• • Can read and speak English
• • Capable of providing informed consent
• • Has not previously received three series HPV vaccine
• • No contraindications to receiving HPV vaccine (i.e. history of anaphylactic allergy to later, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant).
• Exclusion Criteria:
• • Has contraindications to receiving the HPV vaccine i.e., history of an anaphylactic allergy to latex, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant)